Citing Decline in Glyphosate-Based Product Sales, Bayer Lowers Yearly Outlook
Company now expects around $53 billion in sales for 2023.
The Bayer Group revealed that its full-year outlook has been lowered, with a significant dive in glyphosate-based product sales. According to a company press release, adjustments now forecast an estimated $53 billion in sales before taxes, crediting information from its 2022 average monthly exchange rates.
Previously, the organization alluded to lowering the outlook when communicating its first quarter results. It also stated that a combination of decline in prices and lower volumes due to channel de-stocking increased pressure on making the decision. Reportedly, Bayer expects a negative group net income of an estimated $2.2 billion dollars for the second quarter of the year, with detailed results being released early next month.
Reference: Bayer lowers full-year outlook. Bayer. July 24, 2023. Accessed July 26, 2023. https://www.bayer.com/media/en-us/bayer-lowers-full-year-outlook/
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
